Skip to main content

Advertisement

Table 3 The baseline characteristics of 224 patients with HCC based on the stratification with the TNM staging system

From: Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization

Characteristic   TNM early stage   TNM advanced stage
Total ( n  = 71) Antiviral treatment group ( n  = 23) Non-antiviral group ( n  = 48) P value   Total ( n  = 153) Anti-viral group ( n  = 57) Non-antiviral group ( n  = 96) P value
Sex (males:females)   108:11663:8 22:1   41:7 0.261   146:7 56:1 90:6 0.198
Age a (years)   54.5 (45.0, 62.0) 55.0 (48.0, 62.0) 52.5 (42.0, 62.5) 0.690   46.0 (36.5, 57.0) 45.0 (37.0, 53.0) 48.0 (36.0, 57.0) 0.427
WBC (×10 9 /L)   6.29 ± 1.91 6.38 ± 1.94 6.25 ± 1.91 0.649   6.84 ± 2.20 6.38 ± 1.83 7.11 ± 2.35 0.090
HBG (g/L)   139.02 ± 19.74 140.77 ± 17.61 138.18 ± 20.81 0.609   137.39 ± 20.57 136.79 ± 24.06 137.74 ± 18.30 0.783
PLT (×10 9 /L)   153.37 ± 79.37 147.78 ± 77.98 156.04 ± 80.70 0.746   192.22 ± 83.71 179.39 ± 90.93 199.84 ± 78.62 0.052
ALT (U/L)   50.19 ± 32.14 55.11 ± 28.20 47.83 ± 33.89 0.136   62.18 ± 43.58 69.38 ± 49.83 57.90 ± 39.06 0.289
AST (U/L)   65.63 ± 44.32 60.38 ± 29.26 68.14 ± 50.05 0.883   93.83 ± 67.54 103.59 ± 69.70 88.03 ± 65.90 0.092
ALB (g/L)   40.14 ± 4.59 40.40 ± 4.82 40.02 ± 4.52 0.976   40.08 ± 4.32 38.86 ± 4.41 40.80 ± 4.13 0.009
TBIL (μmol/L)   15.72 ± 6.68 16.09 ± 6.76 15.54 ± 6.71 0.811   16.77 ± 8.00 18.40 ± 9.07 15.81 ± 7.16 0.056
AFP a (ng/mL)   197.70 (7.72, 3065) 63.68 (5.12, 804.7) 650 (9.33, 9419.50) 0.074   4682 (202.80, 76308) 7097 (363.6, 85094) 4571 (106.58, 67557.50) 0.522
AFP (<1,000 ng/mL:>1,000 ng/mL)      47:24 19:4 28:20 0.043   61:92    20:37     41:55 0.352
PT (s)   12.46 ± 2.34 12.77 ± 2.47 12.31 ± 2.28 0.373   12.63 ± 1.96 12.85 ± 1.88 12.50 ± 2.00 0.103
APPT (s)   27.66 ± 3.76 27.57 ± 4.35 27.71 ± 3.50 0.749   28.08 ± 3.89 28.48 ± 3.39 27.85 ± 4.16 0.127
HBeAg positive:negative       15:56     7:16 41:78:40 0.184         38:115 17:40     21:75 0.271
HBV DNA (log 10 IU/mL)   4.58 ± 1.93 5.24 ± 1.97 4.26 ± 1.84 0.033   4.97 ± 1.83 5.60 ± 1.39 4.59 ± 1.95 0.001
Cycles of TACE (one:more than one)       43:28      8:15     35:13 0.002     90:63 29:28     61:35 0.124
Resection after TACE (yes:no)       11:60      3:20       8:40 1.000         8:145      4:53       5:92 0.471
Local therapy after TACE (yes:no)       29:42   12:11     17:31 0.179        20:133    11:46       9:87 0.078
Sorafenib use after TACE (yes:no)         5:66     3:20       2:46 0.320         7:146      3:54       4:92 0.712
Subsequent therapy (yes:no)       37:34 15:8       22: 26 0.126        30:123    15:42     15:81 0.107
Chemotherapeutic agents (epirubicin only: >2 agents)   19:52 5:18     14:34 0.508        34:119    13:44     21:75 0.893
  1. aThe values are presented as median followed by interquartile (P25 and P75) in the parentheses. Abbreviations as in Table 1.